Cardiac resynchronization therapy in patients with renal dysfunction: keep calm and carry on.

Abstract

Journal of Cardiovascular ElectrophysiologyVolume 25, Issue 11 p. 1196-1198 Editorial Comment Cardiac Resynchronization Therapy in Patients with Renal Dysfunction: Keep Calm and Carry On KEVIN P. JACKSON M.D., KEVIN P. JACKSON M.D. Division of Clinical Cardiac Electrophysiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USASearch for more papers by this authorJONATHAN P. PICCINI M.D., M.H.S., Corresponding Author JONATHAN P. PICCINI M.D., M.H.S. Division of Clinical Cardiac Electrophysiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USAAddress for correspondence: Jonathan P. Piccini, M.D., M.H.S., Electrophysiology Section, Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27705, USA. Fax: 919-668-7128; E-mail: [email protected]Search for more papers by this author KEVIN P. JACKSON M.D., KEVIN P. JACKSON M.D. Division of Clinical Cardiac Electrophysiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USASearch for more papers by this authorJONATHAN P. PICCINI M.D., M.H.S., Corresponding Author JONATHAN P. PICCINI M.D., M.H.S. Division of Clinical Cardiac Electrophysiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USAAddress for correspondence: Jonathan P. Piccini, M.D., M.H.S., Electrophysiology Section, Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, P O Box 17969, Durham, NC 27705, USA. Fax: 919-668-7128; E-mail: [email protected]Search for more papers by this author First published: 31 July 2014 https://doi.org/10.1111/jce.12502Citations: 1 K.P.J. receives research funding from and serves as a consultant to Medtronic. J.P.P. receives research funding from ARCA biopharma, Boston Scientific, GE Healthcare, and Johnson & Johnson, and serves as a consultant to Janssen Pharmaceuticals, Medtronic, and Spectranetics. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume25, Issue11November 2014Pages 1196-1198 RelatedInformation